POLYCYCLIC INDAZOLE DERIVATIVES AND THEIR USE AS ERK INHIBITORS FOR THE TREATMENT OF CANCER

Disclosed are the ERK inhibitors of formula 1.0: (Chemical formula should be inserted here as it appears on abstract in paper form) and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring...

Full description

Saved in:
Bibliographic Details
Main Authors TSUI HON CHUNG, DESAI JAGDISH, DENG YONGQI, NAN YANG, PALIWAL SUNIL, SHIH NENG YANG, WANG JAMES, KELLY JOSEPH, DOLL RONALD, ZHU LIANG, ALHASSAN ABDUL BASIT, GAO XIAOLEI, SHIPPS GERALD W. JR, ZHU HUGH, COOPER ALAN, BOGA SOBHANA BABU, PATEL MEHUL
Format Patent
LanguageEnglish
Korean
Published 09.03.2010
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Disclosed are the ERK inhibitors of formula 1.0: (Chemical formula should be inserted here as it appears on abstract in paper form) and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
Bibliography:Application Number: KR20097027487